DoD Memo Recalls 'Essential' Civilian Workers
Client Alert | 1 min read | 10.09.13
On October 5, Secretary Hagel issued guidance relating to DoD's implementation of the Pay Our Military Act (POMA), which passed just hours before the government "shutdown" at midnight on September 30 and provides for funding certain DoD functions while interim or full-year appropriations for FY 2014 are not in effect. The memo, crafted in consultation with DOJ, states that POMA permits funding for active duty military and civilian employees "whose responsibilities provide support to service members providing active service and their families" and "contribute to sustaining capabilities and Force Readiness" (a list which at least initially did not include DCAA auditors, CIO functions, or DCMO functions, although it appears that at least some auditors at some locations have been recalled) and permits expenditure of "such sums as are necessary to provide pay and allowances to contractors of DoD who[m] the Secretary determines are providing support to members of the Armed Forces in active service" (though the memo notes that DoD lawyers are still analyzing what that means).
Contacts
Insights
Client Alert | 4 min read | 09.15.26
GAO Indicates Reasonable Conflict of Interest Investigation Must Include Inquiry of Involved Firm
The U.S. Government Accountability Office’s (GAO) recent decision in Viderity Inc.—Costs, B-424422.5, Sept. 1, 2026, offers useful insight into what constitutes a legally sufficient conflict of interest investigation. The decision arose in an unusual procedural posture: Viderity initially protested, alleging that an agency evaluator had a personal conflict of interest. After the agency took corrective action, Viderity filed a cost entitlement claim requesting that GAO direct the agency to reimburse Viderity’s protest costs. In evaluating that claim, GAO assessed whether Viderity’s underlying protest ground was “clearly meritorious.”
Client Alert | 3 min read | 09.15.26
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance

